: Objectives. The objective of this study was to examine the effects of treatment with atorvastatin, α‐tocopherol and the combination of both, on lipoproteins and oxidative stress in dialysis patients.Design and setting. This double‐blind randomised placebo‐controlled trial was performed at the dialysis department of a non‐university hospital.Subjects, intervention and measurements. A total of 44 clinically stable, non‐diabetic patients on dialysis therapy (23 on haemo‐ and 21 on peritoneal‐dialysis) without manifest cardiovascular disease were included in this study. They were randomised for treatment during a period of 12 weeks with 40 mg atorvastatin + placebo α‐tocopherol (group 1) once daily, 800 IU α‐tocopherol + placebo atorvastatin once daily (group 2), 40 mg atorvastatin + 800 IU α‐tocopherol once daily (group 3), or placebo atorvastatin + placebo α‐tocopherol once daily (group 4). Assessment of lipid profile and oxidative stress was performed at the start of the study and after 12 weeks of treatment.Results. Treatment with atorvastatin reduced total cholesterol, triglycerides (TG), low‐density lipoprotein (LDL) cholesterol, apolipoprotein B (apoB) and levels of oxidised LDL (oxLDL) with 30–43%. It had no influence on LDL oxidisability. Additional supplementation with α‐tocopherol had no effect on lipid profile and oxLDL levels but decreased in vitro LDL oxidisability. No side‐effects were observed.Conclusions. Treatment with atorvastatin is effective in lowering plasma total cholesterol, TG, LDL, apoB and oxLDL in a population of stable dialysis patients and might therefore be an effective tool in improving the poor cardiovascular outcome in these patients. Supplementation of α‐tocopherol to atorvastatin had beneficial effects on in vitro LDL oxidisability and might therefore be of additional value. Further research on the clinical effects of treatment with atorvastatin in combination with α‐tocopherol is necessary.

Publications with shared reference:

0 publications found